Blackstone Inc. purchased a new stake in Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,070,684 shares of the company's stock, valued at approximately $6,730,000. Blackstone Inc. owned about 2.99% of Inhibikase Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. Stifel Financial Corp bought a new stake in shares of Inhibikase Therapeutics during the 4th quarter valued at about $43,000. Alpine Global Management LLC acquired a new stake in Inhibikase Therapeutics in the 4th quarter valued at approximately $48,000. Caxton Corp bought a new stake in Inhibikase Therapeutics during the 4th quarter valued at $53,000. Northern Trust Corp bought a new stake in Inhibikase Therapeutics during the 4th quarter valued at $208,000. Finally, Barclays PLC acquired a new position in Inhibikase Therapeutics during the 4th quarter worth $273,000. 3.81% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "neutral" rating on shares of Inhibikase Therapeutics in a research report on Friday, March 28th.
Read Our Latest Stock Report on IKT
Inhibikase Therapeutics Price Performance
Shares of Inhibikase Therapeutics stock traded down $0.10 during trading on Friday, hitting $2.00. The stock had a trading volume of 109,431 shares, compared to its average volume of 233,621. The business has a fifty day moving average of $2.10 and a two-hundred day moving average of $2.51. Inhibikase Therapeutics, Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $4.20. The firm has a market cap of $148.68 million, a P/E ratio of -0.75 and a beta of 1.01.
Inhibikase Therapeutics Company Profile
(
Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Featured Articles
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
